Upstream / Downstream
Explore pathways related to this product.
CST Antibody Performance Guarantee
Find answers on our FAQs page.
PTM information and tools available.
Phospho-Ack1 (Tyr857/858) Antibody #3137
This product is discontinued
Gallery: Phospho-Ack1 (Tyr857/858) Antibody #3137
Phospho-Ack1 (Tyr857/858) Antibody detects overexpressed levels of Ack1 only when phosphorylated at Tyr857/858. This antibody does not cross-react with other tyrosine-phosphorylated tyrosine kinases.
Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr857/858 of human Ack1. Antibodies are purified by protein A and peptide affinity chromatography.
Ack1 and Ack2 (activated cdc42-associated kinase 1 and 2) are non-receptor tyrosine kinases that consist of a tyrosine kinase core, an SH3 domain, a cdc42/Rac-binding (CRIB) domain, a Ralt homology region and a proline-rich region (1,2). Ack1 and 2 are the only two tyrosine kinases known to interact with cdc42. Both Acks are activated by growth factors including EGF and PDGF, as well as by activated integrins through cell adhesion, and may serve to link receptor tyrosine kinase or G protein-coupled receptor signaling with cdc42. Acks may regulate cell growth, morphology and motility (3,4). Recent findings indicate that Ack1 may play a role in prostate tumorigenesis, making it a potential drug target for this type of cancer (5).
Phosphorylation of Ack1 on Tyr857 and Tyr858 on Ack1 was identified at Cell Signaling Technology (CST) using PhosphoScan®, CST's LC-MS/MS platform for phosphorylation site discovery as well as other publications using MS technology (5,6). Phosphorylation of Ack1 at Tyr857/858 was observed in select carcinoma cell lines and in tumors.
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.